Loading mutual fund details…
SBI HEALTHCARE OPPORTUNITIES FUND - REGULAR PLAN -GROWTH is an equity scheme managed by SBI Mutual Fund. Over rolling three-year windows since inception, investors earned a median compounded return of 22.38%, with the bottom and top quartiles at 18.12% and 24.50% respectively. It has ranked in the top half of its category for 7 of the last 12 reported years. Risk-adjusted return (Sharpe ratio) is 0.00. The total expense ratio is 1.90% on assets of ₹4,323Cr. The fund is currently managed by Mr. Tanmaya Desai, appointed within the last year.
Lower is better.
This scheme classifies as Large-Growth on the 3x3 equity style box, with 66% of its portfolio classified as of 2026-04-30.
| Holding | Sector |
|---|
| Window | Min | P25 | Median |
|---|
Point-in-time CAGRs cherry-pick a single start date. The chart below shows the distribution of every possible rolling start over the fund's history, so you see the range of investor outcomes — not just one date's number.
Backtested SIP outcomes across both rolling-window scenarios and named historical stress events (COVID, Election uncertainty, Russia/Ukraine, etc.), plus per-manager alpha during their tenure on this scheme.
Same fund, monthly SIPs over rolling 1/3/5-year windows.
| Scheme | AMC | AUM | TER | 3Y |
|---|
Mutual fund investments are subject to market risks. Read all scheme-related documents carefully. Past performance is not indicative of future results. MintByte is an AMFI-registered Mutual Fund Distributor (ARN-314872) and APMI member (APRN-01658). MintByte does not issue buy/sell recommendations on specific securities — the site is an educational data and analytics platform. Star ratings on this page reflect a 3-year category-quartile position computed in-house and are educational only.
Mutual fund schemes are subject to market risk. Read all scheme-related documents carefully before investing. Past performance is not indicative of future results. MintByte is an AMFI-registered mutual fund distributor (ARN-314872). MintByte does not issue buy/sell recommendations on specific securities — the site is an educational data and analytics platform. Not investment advice. Methodology · How we earn.
In-house derivations using 3-year daily NAV vs benchmark. See methodology.
| Weight |
|---|
| Krishna Institute Of Medical Sciences Limited | Healthcare | 2.47% |
| Sai Life Sciences Limited | Healthcare | 2.47% |
| Sudeep Pharma Limited | Healthcare | 2.23% |
| Sector | Holdings | Weight |
|---|---|---|
| Pharmaceuticals & Biotechnology | 2 | 64.35% |
| Healthcare Services | 1 | 24.43% |
| Chemicals & Petrochemicals | 1 | 3.35% |
| Healthcare Equipment & Supplies | 1 | 2.24% |
| Retailing | 1 | 0.30% |
Active bets vs the average Equity fund. Biggest deviations shown first.
Accent bar = fund's actual sector weight. Vertical black tick = category average for the same sector. Green overlay = overweight, dashed red = underweight. The biggest active bets show first.
How crowded into the same stocks is this fund vs the largest fund in its category?
Category leader = highest-AUM scheme in the same SEBI category. A high overlap-of-weight number means the fund is concentrated into the same names as the leader (crowded); a low one means it's genuinely differentiated.
| P75 |
|---|
| Max |
|---|
| Positive % |
|---|
| 1Y | -14.59% | 2.39% | 18.44% | 36.97% | 62.51% | 81.7% |
| 3Y | 14.41% | 18.12% | 22.38% | 24.50% | 30.17% | 100.0% |
| 5Y | 14.75% | 15.91% | 18.18% | 20.43% | 24.75% | 100.0% |
Each cell is one year. Q1 = top quartile within the AMFI category for that period. Cell label is the last two digits of the year.
Top-10 weight 7.2% means the portfolio is broad — even the top names don't dominate. Effective-N is the inverse Herfindahl index — a measure of "how many positions effectively drive the fund" after weighting. Category: Equity.
Compounding maths on a notional ₹10 lakh lumpsum at 12% gross annual return. Green bar is what you'd have without the fee; red overlay is the fee drag. Fee is constant in this scenario — actual outcomes depend on real returns and any future TER changes.
Each row is a back-tested SIP — monthly contribution over the regime's duration, no fees adjustment beyond NAV-baked TER. XIRR is the annualised IRR of those cashflows; Abs return is the absolute cash-on-cash; Max DD is the deepest drawdown experienced mid-investment. Past performance is not indicative of future results.
Alpha is the annualised excess return vs benchmark over the manager's tenure on this scheme. Beat-benchmark = total return beat the index over the same window.
| 5Y |
|---|
| Star |
|---|
| UTI Healthcare Fund - Regular Plan - Growth Option | UTI Mutual Fund | ₹1,144 Cr | 2.30% | +25.58% | +13.65% | 3★ |
| Mirae Asset Healthcare Fund -Regular Growth | Mirae Asset Mutual Fund | ₹2,939 Cr | 2.04% | +24.16% | +13.98% | 3★ |
| Aditya Birla Sun Life Pharma and Healthcare Fund-Regular-Growth | Aditya Birla Sun Life Mutual Fund | ₹901 Cr | 2.27% | +22.88% | +12.34% | 3★ |
| Tata India Pharma & Healthcare Fund-Regular Plan-Growth | Tata Mutual Fund | ₹1,325 Cr | 2.21% | +21.66% | +13.09% | 3★ |
| DSP Healthcare Fund - Regular Plan - Growth | DSP Mutual Fund | ₹3,142 Cr | 2.12% | +21.24% | +13.81% | 3★ |
| ITI Pharma and Healthcare Fund - Regular Plan - Growth Option | ITI Mutual Fund | ₹230 Cr | 4.84% | +19.12% | — | 3★ |
| LIC MF Healthcare Fund-Regular Plan-Growth | LIC Mutual Fund | ₹85 Cr | 2.44% | — | — | 2★ |
| Kotak Healthcare Fund - Regular Plan - Growth Option | Kotak Mahindra Mutual Fund | ₹496 Cr | 2.54% | — | — | 2★ |
| WhiteOak Capital Pharma and Heathcare Fund Regular Plan Growth | WhiteOak Capital Mutual Fund | ₹603 Cr | 2.57% | — | — | 2★ |
| PGIM India Healthcare Fund - Regular Plan - Growth Option | PGIM India Mutual Fund | ₹92 Cr | 2.47% | — | — | 1★ |